14008-44-7
Chemical Structure
Metopimazine
Synonym(s): EXP999; RP9965
- CAS No.: 14008-44-7
- Formula:C22H27N3O3S2
- Molecular Weight:445.60
IUPAC Name: 1-(3-(2-(methylsulfonyl)-10H-phenothiazin-10-yl)propyl)piperidine-4-carboxamide
InChIKey: BQDBKDMTIJBJLA-UHFFFAOYSA-N
SMILES: O=C(N)C1CCN(CC1)CCCN2C3=C(SC4=CC=C(C=C24)S(=O)(C)=O)C=CC=C3
Biological Activity: Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Metopimazine | 99.75% | Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metopimazine (Standard) | ≥98% | Metopimazine (Standard) is the analytical standard of Metopimazine. This product is intended for research and analytical applications. Metopimazine (EXP999) is a phenothiazine derivative used to prevent emesis during chemotherapy. Metopimazine belongs to the anti-dopaminergic anti-emetics (ADA) class. Metopimazine can be used for the research of gastroenteritis (GE) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metopimazine-d6 | Metopimazine-d6 (EXP999-d6; RP9965-d6) is the deuterium labeled Metopimazine (HY-116578). Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Victoire Roussel, et al. Estimating the excess of inappropriate prescriptions of anti-dopaminergic anti-emetics during acute gastroenteritis epidemics in France. Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1080-5. [Content Brief]
- [2]. Mozgova O, et al. A new spectrophotometric method for the quantitative determination of Metopimazine based on the absorbance of its sulfoxide[J]. Chemical Papers, 2024, 78(11): 6585-6591.
- [3]. Jolliet P, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res. 2007 Jul;56(1):11-7. [Content Brief]
